Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.34 USD
Change Today +0.01 / 3.03%
Volume 266.1K
CRDC On Other Exchanges
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

cardica inc (CRDC) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/22/14 - $1.32
52 Week Low
09/1/15 - $0.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CARDICA INC (CRDC)

Related News

No related news articles were found.

cardica inc (CRDC) Related Businessweek News

No Related Businessweek News Found

cardica inc (CRDC) Details

Cardica, Inc. designs, manufactures, and markets automated anastomotic systems for use by cardiac surgeons to perform coronary bypass surgery in the United States and internationally. It provides C-Port Distal Anastomosis systems, including C-Port xA Anastomosis systems to perform an end-to-side distal anastomosis by attaching the end of a bypass graft to a coronary artery downstream of an occlusion or narrowing; C-Port Flex A Anastomosis systems to enable automated anastomoses to be performed as part of coronary artery bypass grafting procedures; and PAS-Port Proximal Anastomosis systems to perform an end-to-side proximal anastomosis between a saphenous vein and the aorta. It also offers endoscopic microcutter products comprising MicroCutter XCHANGE 30, MicroCutter FLEXCHANGE 30, and MicroCutter XCHANGE 45 cartridge based microcutter devices to facilitate endoscopic procedures requiring cutting and stapling; and MicroCutter XPRESS 30 and MicroCutter XPRESS 45 multi-fire endolinear microcutter devices for the bariatric and thoracic surgery markets. In addition, the company licenses its intellectual property in the robotics field in diagnostic or therapeutic medical procedures. The company markets its Port Distal Anastomosis systems through its direct sales force, as well as through independent manufacturers’ representatives and distributors. The company was formerly known as Vascular Innovations, Inc. and changed its name to Cardica, Inc. in November 2001. Cardica, Inc. was founded in 1997 and is headquartered in Redwood City, California.

cardica inc (CRDC) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $455.8K
Vice President of Sales and Marketing
Total Annual Compensation: $114.6K
Compensation as of Fiscal Year 2014.

cardica inc (CRDC) Key Developments

Cardica Inc. Announces Unaudited Financial Results for the Fourth Quarter and Full Year Ended June 30, 2015

Cardica Inc. announced unaudited financial results for the fourth quarter and full year ended June 30, 2015. Total product sales and net revenues were approximately $0.7 million for the fiscal 2015 fourth quarter, compared with $1.0 million for the fiscal 2014 fourth quarter. The net loss for the fiscal 2015 fourth quarter was approximately $3.9 million, or $0.04 per diluted share. The net loss before the deemed preferred stock dividend for the fiscal 2014 fourth quarter was approximately $4.7 million, or $0.06 per share. GAAP results include a deemed (non-cash) preferred stock dividend of $1.9 million, representing a beneficial conversion charge due to the difference between the common stock price and conversion price on the closing date of the company's public offering completed in the fourth quarter of fiscal 2014, resulting in a net loss allocable to common stockholders of $6.6 million, or $0.09 per diluted share. Loss from operations was $3,760,000 against $4,548,000 for the same period of last year. Total net revenue was approximately $3.0 million for the year ended June 30, 2015, compared with $3.6 million for the year ended June 30, 2014. Net loss for the year ended June 30, 2015, was approximately $19.2 million, or $0.22 per diluted share. Net loss for fiscal 2014 was approximately $17.0 million. Net loss allocable to common stockholders after taking into account the $1.9 million deemed dividend was $18.9 million, or a loss of $0.32 per diluted share. Loss from operations was $18,783,000 against $16,501,000 for the same period of last year.

Cardica, Inc. Announces Resignation of Bernard A. Hausen as Chief Executive Officer, President and as Member of the Board of Directors

Cardica Inc. announced that Bernard A. Hausen, M.D., Ph.D., has informed the Board of Directors that after more than 15 years leading the company, he will step down as chief executive officer, president and as a member of the Board of Directors. By request of the company, Dr. Hausen has agreed to stay on in his current roles while the Board of Directors conducts a search for a new CEO as well as to provide a period of time to transition his duties to the new CEO. At the present time, the Board of Directors believes the transition period will be completed by December 31, 2015.

Cardica Inc. to Report Q4, 2015 Results on Aug 06, 2015

Cardica Inc. announced that they will report Q4, 2015 results at 5:00 PM, Eastern Standard Time on Aug 06, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRDC:US $0.34 USD +0.01

CRDC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Olympus Corp ¥4,115 JPY -60.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CRDC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.8x
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDICA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at